Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Sign in
Join now
Dirk von Lewinski MD

Dirk von Lewinski MD

Associate Professor, Division of Cardiology, Medical University of Graz, Graz, Austria

Dr. von Lewinski is an Associated Professor and Head of Research Unit, Myocardial energetics und metabolism at the Medical University Graz, Austria. He is a specialist in internal medicine, (interventional) cardiology and intensive care medicine. He has performed extensive basic research on the myocardial energetics and metabolism as well as different drug effect on the myocardium and its energy balance. He is National Leader in several large outcome trial and Co-PI of the investigator-initiated EMMY trial on empagliflozin in acute myocardial infarction.

Disclosures

Dr. von Lewinski reports the following:
  • Speaker fees: AstraZeneca, Bayer, DaiichiSankyo, Novartis, Pfizer, Sanova, Servier, Sanofi, Orion
  • Advisor for: Bayer, Amgen, Recardio, TLL
  • Unrestricted grants by: Pfizer, Boehringer Ingelheim, Orion, Novartis, MSD
  • Advisory Boards for: DaiichiSankyo, Lilly, AstraZeneca, Sanofi
  • Scientific Board: Recardio Inc., Vaxxinity

Recent Contributions to PracticeUpdate:

  1. Effect of Dapagliflozin Across the Range of LVEF in Patients With Heart Failure

Most Read This Week

Recently Updated